Pfizer India’s 4QFY22 earnings beat our/consensus estimate by 8.8%/20.8% as margins came in better than expected. Lower cost of sales and QoQ decline in staff costs aided margins in 4QFY22.
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.